Skip to main content
SpringerLink
Log in

Erfolgreiche symptomatische Therapie einer Epidermodysplasia verruciformis mit Imiquimod 5% Creme

Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream

  • Übersichten
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Wir berichten über einen 19-jährigen Patienten mit einer Epidermodysplasia verruciformis (EV). Zum einen handelt es sich um eine Genodermatose, weiterhin wurden bisher als wesentliche pathogenetische Faktoren humane Papillomviren sowie Sonnenexposition definiert. Diese werden als mitentscheidend dafür angesehen, dass 30–70% der Patienten im Laufe von Jahrzehnten Karzinome auf dem Boden einer EV entwickeln. Die verschiedenen Therapieansätze einer EV sind bisher unbefriedigend. Im vorliegenden Fall konnte bei dem Patienten HPV 5b nachgewiesen und die damit assoziierten Hautveränderungen konnten erfolgreich mit Imiquimod 5% Creme behandelt werden.

Abstract

A 19-year-old patient presented with epidermodysplasia verruciformis (EV). In this genodermatosis, pathogenetic factors such as infection by human papilloma viruses as well as sun exposure are considered responsible for the malignant transformation of EV lesions to skin cancer within decades. So far, several therapeutic strategies have been unsatisfactory. In our case HPV 5b was detected and the associated skin lesions were successfully treated with imiquimod 5% cream.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Berthelot C, Dickerson MC, Rady P et al (2007) Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with Imiquimod. J Am Acad 56:882–886

    Article  Google Scholar 

  2. Cricca M, Bonvicini F, Venturoli S et al (2004) Efficient treatment of paraffin-embedded cervical tissue for HPV DNA testing by HC II and PCR assays. J Clin Virol 29:137–140

    Article  CAS  PubMed  Google Scholar 

  3. Fang F, Zhao L, Jiang MJ et al (2006) Epidermodysplasia verruciformis with severe hands and feet deformity successfully treated by surgical excision. Br J Dermatol 155:207–229

    Article  Google Scholar 

  4. Gewirtzman A, Bartlett B, Tyring S (2008) Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis 21:141–146

    Article  PubMed  Google Scholar 

  5. Giampieri S, Storey A (2004) Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses 5 and 18. Br J Cancer 90:2203–2209

    CAS  PubMed  Google Scholar 

  6. Janssen K, Lucker GPH, Houwing RH, Rijssel R van (2007) Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod. Int J Dermatol 46(Suppl 3):45–47

    Article  PubMed  Google Scholar 

  7. Lewandowsky F, Lutz W (1922) Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis). Arch Dermatol Syphilol 14:193–203

    Google Scholar 

  8. Lutzner MA (1978) Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 65:169–182

    CAS  PubMed  Google Scholar 

  9. Majewski S, Jablonska S (2002) Do epidermodysplasia verruciformis human papillomaviruses contribute to malignant and benign epidermal proliferations? Arch Dermatol 138:649–654

    Article  PubMed  Google Scholar 

  10. Majewski S, Jablonska S (2003) Possible involvement of epidermodysplasia verruciformis human papillomaviruses in the immunopathogenesis of psoriasis: a proposed hypothesis. Exp Dermatol 12:721–728

    Article  PubMed  Google Scholar 

  11. Marcuzzi GP, Hufbauer M, Kasper HU et al (2009) Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J Gen Virol 90:2855–2864

    Article  CAS  PubMed  Google Scholar 

  12. Michael KM, Waterboer T, Pfister H et al (2010) Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. J Invest Dermatol 130:841–848

    Article  CAS  PubMed  Google Scholar 

  13. Nindl I, Gottschling M, Stockfleth E (2007) Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23:247–259

    CAS  PubMed  Google Scholar 

  14. Orth G (2006) Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 18:362–374

    Article  CAS  PubMed  Google Scholar 

  15. Orth G (2005) Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: Guilty or innocent? J Invest Dermatol 125:xii–xiii

    Article  CAS  PubMed  Google Scholar 

  16. Orth G (2008) Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 321:59–83

    Article  CAS  PubMed  Google Scholar 

  17. Qu Q, Jiang G, Cruz Y et al (1997) PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 35:1304–1310

    CAS  PubMed  Google Scholar 

  18. Ramoz N, Rueda LA, Bouadjar B et al (2002) Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 32:579–581

    Article  CAS  PubMed  Google Scholar 

  19. Sotlar K, Diemer D, Dethleffs A et al (2004) Detection and typing of human papillomavirus by E6 nested multiplex PCR. J Clin Microbiol 42:3176–3184

    Article  CAS  PubMed  Google Scholar 

  20. Wolf P, Seidl H, Bäck B et al (2004) Increased prevalence of human papillomavirus in hairs plucked from patients with psoriasis treated with psoralen-UV-A. Arch Dermatol 140:317–324

    Article  PubMed  Google Scholar 

  21. Yabe Y, Sakai A, Hitsumoto T et al (1991) A subtype of human papillomavirus 5 (HPV-5b) and its subgenomic segment amplified in a carcinoma: nucleotide sequences and genomic organizations. Virology 183:793–798

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Ricklinger Str. 5, 30449, Hannover, Deutschland

    A. Heratizadeh, B. Völker, K. Wichmann, A. Kapp & T. Werfel

  2. Institut für Pathologie, Neuropathologie und Molekularpathologie, Hannover, Deutschland

    E. Kupsch

Authors
  1. A. Heratizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Völker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Kupsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Wichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Werfel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Heratizadeh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heratizadeh, A., Völker, B., Kupsch, E. et al. Erfolgreiche symptomatische Therapie einer Epidermodysplasia verruciformis mit Imiquimod 5% Creme. Hautarzt 61, 1052–1055 (2010). https://doi.org/10.1007/s00105-010-1998-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-1998-4

Schlüsselwörter

Keywords

Search

Navigation